-Reuters
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program
The FDA has removed the full clinical hold on Protagonist Therapeutics Inc’s (NASDAQ:PTGX) rusfertide clinical studies. The Company provided the requested individual…